Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials

Phase 3positiveremibrutinibPositive

AI Analysis

Summary

Novartis announced positive Phase 3 trial results for remibrutinib, an oral BTK inhibitor, demonstrating significant reduction in relapse rates and favorable safety profile in relapsing multiple sclerosis patients.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

significantly reduces relapse rates and shows favorable safety profile

Importance:7/10

Sentiment:

0.75

Phase 3BTK inhibitorrelapsing multiple sclerosisefficacysafety

Related Companies

$NVS

Read the original article

Published by GlobeNewswire Pharma on September 1, 2026 5:15 AM

Read Original